HESI RN
HESI Pharmacology Questions
Extract:
Question 1 of 5
The health care provider prescribes the antilipemic lovastatin for a client who has exhibited a consistently elevated serum cholesterol level. In evaluating the client’s treatment regimen, which remark by the client indicates to the nurse that the client understands the drug’s treatment protocol?
Correct Answer: B
Rationale: Lovastatin risks hepatotoxicity; avoiding alcohol (
B) reduces liver strain, indicating understanding. Stopping when cholesterol lowers (
A) is incorrect; it’s long-term. Diet restrictions persist (
C). WBC monitoring (
D) is unnecessary.
Question 2 of 5
A client taking atorvastatin becomes an increased serum creatine phosphokinase (CK) level. The nurse should assess the client for the onset of which problem?
Correct Answer: D
Rationale: Atorvastatin can cause myopathy, indicated by elevated CK levels. Muscle tenderness (
D) suggests muscle damage, requiring assessment. Nausea (
A), bruising (
B), and edema (
C) are not typical.
Question 3 of 5
A client with hepatic encephalopathy is receiving lactulose. Which assessment provides the nurse with the nest information to evaluate the client’s therapeutic response to the drug?
Correct Answer: B
Rationale: Lactulose reduces ammonia absorption in hepatic encephalopathy. Serum electrolytes and ammonia levels (
B) assess therapeutic response. Glucose (
A), stool (
C), and hepatic enzymes (
D) are less direct.
Question 4 of 5
The nurse administers risedronate to a client with osteoporosis at 07:00. The client asks for a glass of milk to drink with the medication. Which action should the nurse take?
Correct Answer: D
Rationale: Risedronate requires an empty stomach and plain water (
D) for absorption. Milk (
B) contains calcium, reducing efficacy. Delaying for food (A,
C) is unnecessary.
Question 5 of 5
A client with benign prostatic receives a new prescription of tamsulosin. Which intervention should the nurse use to monitor an adverse reaction?
Correct Answer: C
Rationale: Tamsulosin, an alpha-blocker, risks hypotension, causing dizziness or fainting. Monitoring blood pressure (
C) detects this adverse effect. Urine output (
A), bladder scans (
B), and weights (
D) are unrelated.